At the 2014 Exploratory Clinical Development World Europe, Sylvia Julien, Principal Scientist, Senior Project Leader Global Scientific Affairs and Strategic Sourcing, Ipsen, gave a presentation on “Minimising the immunogenicity of biopharmaceuticals: Current status of monitoring immunogenicity across the R&D value chain.
Download and learn:
- Immunogenicity and influencing factors
- Immunogenicity risk assessment, stage-based
- Conclusion and perspectives
Found this interesting? Join us in 2015 for the 9th annual Exploratory Clinical Development World. The conference is recognised as the premier conference for understanding the right strategies and methods to assess safety & efficacy and make timely go/no go decisions. Learn how to avoid the expense of carrying ineffective novel agents into full scale clinical development.